A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

Recruiting now · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumors

In brief

The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

Key facts

Study ID: NCT05867420
Run by: AskGene Pharma, Inc.
People needed: 594
Starts: 2023-08-02
Expected to finish: 2028-06-30
Last updated by the study team: 2026-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed advanced malignant tumor that is refractory to or intolerant of all standard therapy or for which no standard therapy is available.
ECOG performance status of ≤ 2.
Life expectancy of ≥ 3 months.
The results of the laboratory tests must meet all criteria.

You may not qualify if…

Patients have received antitumor therapy during the first 4 weeks before study drug use.
Received a live attenuated vaccine within 4 weeks prior to C1D1.
Known cerebral parenchymal metastasis or meningeal metastasis.
History of serious cardiovascular or cerebrovascular diseases.
Active or recurrent autoimmune diseases.
History of ascites or pleural effusion requiring drainage.
Pregnant or lactating or planning to become pregnant at any time during the study, including the Follow-up Period.

Where it is running

Columbia University Irving Medical Center — New York, New York, United States (enrolling)
UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China (enrolling)
Peking University Cancer Hospital — Beijing, Beijing Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.